Northland raised the firm's price target on BioLife Solutions to $34 from $31 and keeps an Outperform rating on the shares, which were also named a 2026 Top Pick. Following its re-establishment as a pure play and its control of the biopreservation layer in cell and gene therapy development, BioLife is "structurally locked into large pharma and biotech programs from initiation through commercialization," the analyst tells investors.
